Immunovant shares jumped after the company disclosed early Phase 2b findings for IMVT-1402, a next-generation FcRn inhibitor in difficult-to-treat rheumatoid arthritis (D2T RA). The study includes patients who failed at least two prior advanced therapies, including TNF and JAK inhibitor exposure, and remains ongoing. Immunovant reported 16-week open-label responses across ACR20, ACR50, and ACR70 assessments, while management indicated next steps include further analysis and engagement with the FDA on the path forward. The update reframes FcRn targeting as a potential late-line option in a crowded RA landscape. For investors and developers, it adds incremental signal for FcRn biology in autoimmune disease, though the trial is still early and confirmatory work remains pending.